Industrial Designs
The professionals at Luiz Leonardos & Advogados provide advice on all matters related to industrial designs, such as consulting, drafting, filing, and monitoring registration applications in Brazil and abroad. We have solid expertise in monitoring third-party cases and filing oppositions, as well as nullity requests, both in the administrative and judicial spheres, being capable of taking and enforcing all necessary measures to maintain and protect our clients' rights.
Other practice areas
Competition and Antitrust Law
Inhibiting anti-competitive practices is of utmost importance today, and it also concerns the enforcement of intellectual property rights. We advise our clients on the prevention and combat of crimes against the national economic order, representing them before the Administrative Council for Economic Defense (CADE) and other antitrust bodies, particularly in the defense of industrial property rights.
Entertainment and Advertising Law
Luiz Leonardos & Advogados provides legal assistance to players in the entertainment and advertising markets, including legislative counseling, analysis of self-regulatory standards, and representation before CONAR (the Brazilian Advertising Self-Regulation Council). Our practice also encompasses the production of agreements, the licensing and assignment of copyright, image rights releases, and other related services in this field.
Regulatory and Health Law
Luiz Leonardos & Advogados has an exclusive team to conduct procedures with the National Health Surveillance Agency (ANVISA). We advise clients on regulatory matters and act to maintain clients' exclusivity rights over data packages, as provided by the TRIPS Agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights) and based on local provisions regulating unfair competition. These rights are essential for research-based pharmaceutical companies, which need to send large volumes of information to ANVISA to demonstrate the safety and efficacy of their product innovations. In certain situations, compliance with exclusivity rights over data packages is the only way to prevent generic industry companies from using the innovative manufacturer's data package to obtain approval for their generic versions, instead of conducting their own clinical tests.